Heliad Equity Partners — New investments under new management

Heliad (XETRA: HPBK)

Currency in EUR

Last close As at 05/12/2023


0.00 (0.00%)

Market capitalisation


More on this equity

Research: Investment Companies

Heliad Equity Partners — New investments under new management

Heliad Equity Partners (HEP) has recently become more active, with a mid-double digit million-euro amount invested across several private companies under its new strategy. Following the recent management change (with Falk Schäfers now the sole board member), HEP has been focusing on providing growth equity financing and investing in pre-IPO opportunities. Meanwhile, its H121 results were still largely driven by the change in the share price of flatexDEGIRO, its largest holding representing c 81% of NAV at end-June 2021.

Milosz Papst

Written by

Milosz Papst

Director, Financials

Investment Companies

Heliad Equity Partners

New investments under new management

Investment companies

Scale research report - Update

14 October 2021



Market cap


Share price graph

Share details




Deutsche Börse Scale

Shares in issue


NAV per share at end-June 2021


Business description

Heliad Equity Partners is a Germany-based investment company focused on investing in market-leading private companies across verticals and regions to power their next phase of growth. It aims to provide shareholders with access to pre-IPO market returns while at the same time acting as a gateway to public equity markets for private companies.


Recent acceleration of investment activity aimed at increasing exposure to private companies.

Strong deal origination network.

flatexDEGIRO’s growth story.


Portfolio concentration remains high despite recent new investments.

Management and performance fee charged on a portfolio which is still dominated by one listed holding.

New investment strategy still to be validated.


Milosz Papst

+44 (0) 20 3077 5700

Heliad Equity Partners (HEP) has recently become more active, with a mid-double digit million-euro amount invested across several private companies under its new strategy. Following the recent management change (with Falk Schäfers now the sole board member), HEP has been focusing on providing growth equity financing and investing in pre-IPO opportunities. Meanwhile, its H121 results were still largely driven by the change in the share price of flatexDEGIRO, its largest holding representing c 81% of NAV at end-June 2021.

flatexDEGIRO’s share price highly volatile ytd

HEP reported net income of €68.4m in H121 (versus €32.3m in H120), mostly on the back of the c 86% increase in flatexDEGIRO’s share price during the period. Having said that, we note that the latter has subsequently given up most of the H121 share price gains following its preliminary H121 results release, which may be due to some moderation in the Q221 results following a particularly strong Q121 (albeit expected by the management). HEP’s other operating expenses increased to €6.0m in H121 versus €1.3m in H120, primarily due to the performance fee paid to its investment manager (none was paid in H120).

HEP’s new investment activity picking up

The company has recently announced a number of new private investments, including Enpal (a company active in photovoltaics leasing), Modifi (a digital trade finance platform for SMEs), Upscalio (a company investing in brands that sell on e-commerce marketplaces such as Amazon or Flipkart in India) and Razor Group (another business consolidating third-party merchants on Amazon’s Marketplace). Consequently, we believe HEP has deployed most of its previous cash position. Moreover, it has entered into a ‘collar’ option strategy on flatexDEGIRO’s shares to secure additional funding.

Valuation: Continues to trade at a discount to NAV

HEP’s shares currently trade at a 49% discount to last reported NAV of €20.33 at end-June 2021. However, after accounting for the stake in flatexDEGIRO at the current share price (and all else being equal), we estimate that HEP’s discount to NAV stands at c 28%. While most listed investment companies focused on the private equities market tend to trade at a discount to NAV, we note that the level of HEP’s discount is also influenced by the management and performance fee paid to the investment manager on a portfolio that is still largely dominated by one listed holding. That said, it is worth noting HEP’s recent high new investment activity to build a diverse portfolio of private holdings to justify the fees.

Historical financials




































Source: Heliad Equity Partners. Note: P/NAV based on current share price.

Edison Investment Research provides qualitative research coverage on companies in the Deutsche Börse Scale segment in accordance with section 36 subsection 3 of the General Terms and Conditions of Deutsche Börse AG for the Regulated Unofficial Market (Freiverkehr) on Frankfurter Wertpapierbörse (as of 1 March 2017). Two to three research reports will be produced per year. Research reports do not contain Edison analyst financial forecasts.

flatexDEGIRO drives H121 results

HEP’s net income more than doubled y-o-y to €68.4m in H121 (from €32.3m a year earlier), assisted by a €74.8m net revaluation gain (€33.8m). This was largely driven by 86% share price growth in its main portfolio holding, flatexDEGIRO, in the period (c 81% of Heliad’s NAV at end-H121 versus c 68% at end-FY20). We believe that a small positive impact also came from the 118% share price appreciation of Elumeo, while MagForce’s 25% share price drop had a minor negative effect. Heliad reduced its exposure to the latter two companies in H121 but has not disclosed further details on these holdings.

Other operating expenses increased to €6.0m in H121 from €1.3m in H120, affected by higher management and liability costs of €5.7m in H121 versus €1.1m in H120. These included a €3.8m performance fee (versus zero in H120) and a €1.9m management fee (€1.0m) charged by its investment manager Heliad Management. The former was triggered by Heliad’s FY20 realised profits (compared with a loss in FY19), while the latter increased due to higher NAV at year-end than a year earlier (which is the basis of the calculation of Heliad’s management fee).

Exhibit 1: H121 results highlights




y-o-y change

Income from the sale of financial assets




Other operating income




Gains from revaluation




Book value disposal of financial assets




Depreciation on intangible assets




Other operating expenses




Income from investments




Depreciation of financial assets




Financial income




Financial expenses




Pre-tax profit




Income taxes




Net result for the period




Average number of shares (diluted, in ‘000s)




EPS (diluted, €)




Source: Heliad Equity Partners

The company’s NAV rose by 53% to €20.33 in H121 following the appreciation in flatexDEGIRO’s share price in the period. Its listed equity investments were valued at €168.9m at end-H121 (c 84% of its NAV), while the value of its unlisted holdings was €23.3m (12%). Cash equivalents declined by €14.9m to €9.6m between end-FY20 and end-H121, representing c 5% of its NAV at period-end (versus 19% at end-FY20). Cash outflow in the period included a €7.5m payment for financial assets and securities, which is primarily attributable to the investment in Enpal (see below).

Importantly, after reaching its all-time high at end-H121, flatexDEGIRO’s share price fell c 37% between end-June 2021 and 13 October 2021 (see below for details of recent developments at flatexDEGIRO). We also note that post-period end, management bought put options and sold call options on flatexDEGIRO’s shares (thus entering a ‘collar’ option strategy) with a term to March 2022, which it highlights will provide additional liquidity for the planned investments. HEP’s liquidity was also supported by the issue of 544k shares under its stock option programme in July 2021 (to be registered in Q421), which generated proceeds of c €3.5m.

With respect to other major holdings, it is worth noting the good top-line performance of Springlane, an e-commerce kitchenware business, which in recent years moved from being an online retailer of third-party products to a business based primarily on own brands and a direct-to-customer model. In a recent interview, the company’s CEO highlighted the company generated revenues of €36m in 2020 compared to €19m in 2019 and c €10m in 2017. The company also generated positive EBITDA in 2020.

Resumed investment activity post management change

In April 2021, Juan Rodriguez and Stefan Schütze resigned from the management board at Heliad and FinLab (which had a c 45% stake in Heliad at end-H121). This was linked to the planned strategic realignment of both companies after Bernd Förtsch became the controlling shareholder in FinLab in January 2021 (see more detail in our previous update note). He is also the controlling shareholder at HEP. Rodriguez and Schütze were replaced on HEP’s management board by Falk Schäfers and Matthias Kröner. However, Matthias Kröner resigned from this position in September 2021 based on mutual agreement with the supervisory board and the company. Based on our discussion with Falk Schäfers, we understand that Matthias Kröner joined the management board to streamline Heliad’s and FinLab’s internal processes and his departure was planned from the beginning (the term of his managerial contract was limited to a maximum of one year).

Following these changes, Heliad resumed its investment activity with the total investment volume reaching a mid-double digit million-euro amount to date, according to management. The company has been focused on two main types of investments. Firstly, it has been active in providing growth equity by participating in series A and B rounds with a ticket size of c €3–10m (translating into a c 10% stake in a business). Recent examples include: 1) HEP’s participation in the €20m series B round of Modifi (a digital trade finance platform for SMEs) in September 2021, in which it invested a high single-digit million euro amount as lead investor in exchange for a 7% stake; 2) a single-digit million euro investment in Upscalio (a company investing in brands that sell on e-commerce marketplaces such as Amazon or Flipkart in India) as part of the company’s US$43m funding round in August 2021; and 3) HEP’s investment in Razor Group (another business consolidating third-party merchants on Amazon’s Marketplace), which in May 2021 completed its US$400m funding round (raising US$25m in equity and US$375m in debt). HEP intends to have a seat on the board of its growth equity investments.

Secondly, HEP has been searching for pre-IPO opportunities to participate in series C and later rounds in companies that plan to list in the foreseeable future. HEP made its first pre-IPO investment in Enpal in July 2021, investing a single-digit million-euro amount. Enpal was founded in 2017 and is active in photovoltaics leasing, with over 8,000 customers and more than 4,500 systems installed in 2020. We note that Enpal also completed a €345m debt raise in September 2021 from institutional clients, including funds and accounts managed by BlackRock.

flatexDEGIRO share price down post H121 results

Meanwhile, Heliad’s largest portfolio holding, flatexDEGIRO, reported preliminary H121 results, with a c 76% y-o-y rise in the average number of brokerage clients to 1.6 million and c 41% y-o-y growth in the number of executed transactions to 53 million in the period. At end-H121, it had more than 1.8 million customers with c €40.6bn assets under custody (compared to 1.3 million clients and €31.8bn assets at the start of the period). It benefited from a high level of market uncertainty, resulting in increased volatility and consequently stronger trading activity. In the period, flatexDEGIRO more than doubled its revenues (€226.1m in H121 versus €99.8m in H120), its EBITDA adjusted for non-cash expenses relating to provisions for long-term incentive plans (€107.7m versus €45.4m) and adjusted net profit (€65.7m versus €26.3m). Reported EBITDA was up 24.6% y-o-y to €53.2m.

flatexDEGIRO’s management revised its guidance for FY21, currently targeting between 2.0 million and 2.2 million customers by the end of the year (versus 1.8–2.0 million previously), and 90–110m completed transaction over the year (up from the 75–90m guidance provided at the time of the FY20 results announcement). Despite this progress, its share price fell by c 37% between end-H121 and 13 October 2021. This may be due to some moderation in results in Q221 after an extraordinarily strong Q121 (albeit expected by the company).


Heliad assesses NAV per share based on the valuation of listed and unlisted holdings. It is trading at a 49% discount to its last published NAV of €20.33 at end-June 2021. The discount to its recently published quarterly NAV continues largely to reflect movements in the valuation of flatexDEGIRO as Heliad still had a c 5.2% stake in the company at 13 October 2021, according to Refinitiv data (unlisted holdings are revalued primarily on completion of funding rounds, while the share of listed companies MagForce and Elumeo in Heliad’s NAV is negligible). Following a 37% depreciation in flatexDEGIRO’s share price between 30 June 2021 and 13 October 2021, we estimate that the value of Heliad’s stake in the company declined from c €163m at end-June 2021 to c €106m at 13 October 2021. If we ignore the price movements of other listed stocks and any other factors affecting Heliad’s NAV versus end-June 2021, we arrive at an underlying discount to last reported NAV of c 28%.

Exhibit 2: Heliad’s NAV and share price performance

Exhibit 3: Heliad’s discount to NAV*

Source: Heliad Equity Partners

Source: Heliad Equity Partners, Edison Investment Research. Note: *Discount to NAV as reported.

Exhibit 2: Heliad’s NAV and share price performance

Source: Heliad Equity Partners

Exhibit 3: Heliad’s discount to NAV*

Source: Heliad Equity Partners, Edison Investment Research. Note: *Discount to NAV as reported.

General disclaimer and copyright

Any Information, data, analysis and opinions contained in this report do not constitute investment advice by Deutsche Börse AG or the Frankfurter Wertpapierbörse. Any investment decision should be solely based on a securities offering document or another document containing all information required to make such an investment decision, including risk factors. This report has been commissioned by Deutsche Börse AG and prepared and issued by Edison for publication globally.

Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2021 Edison Investment Research Limited (Edison).


Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt


London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

1185 Avenue of the Americas

3rd Floor, New York, NY 10036

United States of America

Sydney +61 (0)2 8249 8342

Level 4, Office 1205

95 Pitt Street, Sydney

NSW 2000, Australia

More on Heliad

View All

Latest from the Investment Companies sector

View All Investment Companies content

Research: Healthcare

RhoVac — Phase IIb BRaVac study results in H122

After months of industry-wide turbulence due to the COVID-19 pandemic, RhoVac has emerged with a flurry of positive news. In July 2021, the Safety Monitoring Committee gave the green light to continue the lead Phase IIb trial investigating the RV001 cancer vaccine in prostate cancer patients. Patient recruitment was finalised in September 2021, which means the trial is now in its final months, with top-line data expected in H122. Most recently, RhoVac announced that it had retained an international investment bank to prepare for a potential transaction or partnership deal if the data are positive, a strategy which management has consistently communicated since the start of the trial. Our valuation is higher at SEK1.62bn or SEK84.9/share (versus SEK68.5/share previously), mainly due to an increased probability of success.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free